|
|
|
| |
|
|
| |
The latest drug discovery news from News Medical |
|
|
|
| |
 Predict in vivo bioequivalence with greater accuracy
Developing generic drugs requires proving bioequivalence, but standard dissolution tests often miss absorption changes from excipients. Pion’s BioFLUX™ and miniFLUX™ systems measure both simultaneously, revealing excipient effects, flagging high-risk formulations early, and improving alignment with in vivo and regulatory expectations—helping reduce risk and speed development.
| |
|
|
|
|
 | | |  Researchers identified jorumycidine, a new hexacyclic marine alkaloid from the nudibranch Jorunna funebris and its dietary sponge, Haliclona sp., and demonstrated that it exhibits potent nanomolar cytotoxicity against multiple myeloma cells. They also proposed a new biosynthetic route involving cross-species metabolic interplay and an unusual oxazolidine ring that may help stabilize a pharmacologically important scaffold. | | | | |  University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines. | | | | |  The Alliance for Clinical Trials in Oncology is now enrolling patients into a clinical trial aimed at helping women recover from the vaginal side effects of breast cancer treatment. | | | | |  The University of Cincinnati has enrolled the first patients in a new clinical trial that will test the effectiveness of an investigational drug for prosthetic joint infections (PJI). | | | | |  Late breaking results from the phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate non inferiority to paclitaxel/carboplatin followed by letrozole (PC/L) for progression free survival (PFS) in patients with newly diagnosed stage II-IV low grade serous carcinoma of the ovary or peritoneum. | | | | |  Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22. | |
|
|
|
| | How would you rate today's newsletter?
| |
|
|
|
| |
 |
Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now. |
| |
|
|
|
|
|
